Cargando…
A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia
BACKGROUND: Risperidone is one of commonly utilized antipsychotic in clinical practice. Various metabolizing enzymes effect the plasma levels of risperidone and its active metabolite and thus its clinical efficacy. So, we attempted to evaluate the relationship between CYP2D6*10 (rs1065852) and CYP2D...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065128/ https://www.ncbi.nlm.nih.gov/pubmed/30093744 http://dx.doi.org/10.4103/IJPSYM.IJPSYM_83_18 |
_version_ | 1783342807349460992 |
---|---|
author | Chavan, Bir S. Kaur, Gurjit Gupta, Deepti Aneja, Jitender |
author_facet | Chavan, Bir S. Kaur, Gurjit Gupta, Deepti Aneja, Jitender |
author_sort | Chavan, Bir S. |
collection | PubMed |
description | BACKGROUND: Risperidone is one of commonly utilized antipsychotic in clinical practice. Various metabolizing enzymes effect the plasma levels of risperidone and its active metabolite and thus its clinical efficacy. So, we attempted to evaluate the relationship between CYP2D6*10 (rs1065852) and CYP2D6*4 (rs3892097) gene polymorphism and the plasma concentration of risperidone and its metabolite in patients with schizophrenia. METHODOLOGY: It was a 12-week prospective study carried out in patients diagnosed with schizophrenia. The dose of risperidone was increased weekly by 1 mg and rating of psychopathology was done using Positive and Negative Syndrome Scale (PANSS). Quantification of plasma level of risperidone and 9-hydroxyrisperidone was carried out at week 6 and 12 of treatment. The *4 and *10 alleles of CYP2D6 were genotyped and their effect on metabolism of risperidone was assessed. RESULTS: The number of CYP2D6*4 alleles affected the plasma levels of risperidone, 9-hydroxyrisperidone at 6 weeks of treatment but not at 12 weeks. On the other hand, the number of mutated alleles for CYP2D6*10 influenced the dose corrected plasma concentration of risperidone and active moiety at 12 weeks of treatment. The ratio of plasma concentration of risperidone and 9-hydroxyrisperidone was more than one in all study participants, thus, suggesting that they were poor metabolizers of risperidone. CONCLUSION: The polymorphism of CYP2D6*10 affects the steady state plasma concentration of risperidone in Indian patients with schizophrenia. |
format | Online Article Text |
id | pubmed-6065128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60651282018-08-09 A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia Chavan, Bir S. Kaur, Gurjit Gupta, Deepti Aneja, Jitender Indian J Psychol Med Original Article BACKGROUND: Risperidone is one of commonly utilized antipsychotic in clinical practice. Various metabolizing enzymes effect the plasma levels of risperidone and its active metabolite and thus its clinical efficacy. So, we attempted to evaluate the relationship between CYP2D6*10 (rs1065852) and CYP2D6*4 (rs3892097) gene polymorphism and the plasma concentration of risperidone and its metabolite in patients with schizophrenia. METHODOLOGY: It was a 12-week prospective study carried out in patients diagnosed with schizophrenia. The dose of risperidone was increased weekly by 1 mg and rating of psychopathology was done using Positive and Negative Syndrome Scale (PANSS). Quantification of plasma level of risperidone and 9-hydroxyrisperidone was carried out at week 6 and 12 of treatment. The *4 and *10 alleles of CYP2D6 were genotyped and their effect on metabolism of risperidone was assessed. RESULTS: The number of CYP2D6*4 alleles affected the plasma levels of risperidone, 9-hydroxyrisperidone at 6 weeks of treatment but not at 12 weeks. On the other hand, the number of mutated alleles for CYP2D6*10 influenced the dose corrected plasma concentration of risperidone and active moiety at 12 weeks of treatment. The ratio of plasma concentration of risperidone and 9-hydroxyrisperidone was more than one in all study participants, thus, suggesting that they were poor metabolizers of risperidone. CONCLUSION: The polymorphism of CYP2D6*10 affects the steady state plasma concentration of risperidone in Indian patients with schizophrenia. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6065128/ /pubmed/30093744 http://dx.doi.org/10.4103/IJPSYM.IJPSYM_83_18 Text en Copyright: © 2018 Indian Psychiatric Society - South Zonal Branch http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Chavan, Bir S. Kaur, Gurjit Gupta, Deepti Aneja, Jitender A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia |
title | A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia |
title_full | A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia |
title_fullStr | A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia |
title_full_unstemmed | A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia |
title_short | A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia |
title_sort | prospective study to evaluate the effect of cyp2d6 polymorphism on plasma level of risperidone and its metabolite in north indian patients with schizophrenia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065128/ https://www.ncbi.nlm.nih.gov/pubmed/30093744 http://dx.doi.org/10.4103/IJPSYM.IJPSYM_83_18 |
work_keys_str_mv | AT chavanbirs aprospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT kaurgurjit aprospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT guptadeepti aprospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT anejajitender aprospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT chavanbirs prospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT kaurgurjit prospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT guptadeepti prospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia AT anejajitender prospectivestudytoevaluatetheeffectofcyp2d6polymorphismonplasmalevelofrisperidoneanditsmetaboliteinnorthindianpatientswithschizophrenia |